Avalo Therapeutics, Inc. (AVTX)
Nasdaq: AVTX · Pharmaceutical Preparations · Wayne, PA · filing with the SEC since 2012
Who owns Avalo Therapeutics, Inc.
As filed with the SECHolders of 5% or more
11
Fmr LLC holds 10.8% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 7, 2026 says.
Directors and officers
15
report now, of 46 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 11 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 7, 2026 · COMMON STOCK · 9.7% in Aug 6, 2026
Commodore Capital LP
SCHEDULE 13G · filed Jun 18, 2026 · Common Stock, $0.001 par value
TCG Crossover GP II, LLC
SCHEDULE 13G · filed May 12, 2026 · Common Stock, par value $0.001 per share
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value · 5.81% in May 29, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 9.9% in May 15, 2026
Caligan Partners LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 7.2% in May 15, 2026
Affinity Asset Advisors, LLC
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, $0.001 par value per share · 5.5% in May 14, 2026
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Bvf Partners L P/il
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 9.99% in May 15, 2026
Point72 Asset Management, L.P.
SCHEDULE 13G · filed May 26, 2026 · Common Stock, par value $0.001 per share · 3.5% in Feb 17, 2026
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.75% in May 15, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Jan 30, 2026 · Common Stock · reported falling below 5%, from 5.26% in Oct 30, 2025
Patrick J. Crutcher
SCHEDULE 13G/A · filed Aug 27, 2025 · Common Stock, $0.001 Par Value · reported falling below 5%
Ikarian Capital, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 Par Value · reported falling below 5%, from 9.99% in May 15, 2025
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value · reported falling below 5%, from 9.39% in Nov 14, 2025
Logos Global Management LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · reported falling below 5%, from 5.6% in Apr 1, 2026
SilverArc Capital Management, LLC
SCHEDULE 13G · filed Feb 10, 2026 · Class A Common Stock · reported falling below 5%, from 5.48% in Nov 14, 2025
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.22% in Nov 14, 2025
OrbiMed Advisors LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.4% in Feb 17, 2026
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · reported falling below 5%, from 9.5% in May 15, 2026
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 6, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5% in Feb 24, 2026
What AVTX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
AlmataBio Transaction
A company bought · asset acquisition · owns, named in the 10-K filed Mar 23, 2026
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 20, 2025.
Insider tradesForm 4
43sales
0purchases
40sales on a scheduled plan
6people selling
$8.5Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 49 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | 17 | $3.7M | 17 | 0 | $0 |
| Doyle Mittie | Chief Medical Officer | 17 | $3.0M | 17 | 0 | $0 |
| Varki Paul | Chief Legal Officer | 5 | $1.5M | 5 | 0 | $0 |
| Goldman Jonathan | director | 2 | $200,000 | 0 | 0 | $0 |
| Riley Jennifer | Chief Strategy Officer | 1 | $100,000 | 0 | 0 | $0 |
| Chan Mitchell | director | 1 | $100,000 | 1 | 0 | $0 |